Related Experiment Video
Updated: Jan 24, 2026
![Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60786.jpg&w=3840&q=50)
Cercosporin-Photocatalyzed [4+1]- and [4+2]-Annulations of Azoalkenes Under Mild Conditions
Published on: July 17, 2020
2-Aminothiazole-4-carboxamides Enhance Readthrough of Premature Termination Codons by Aminoglycosides
Safwat M Rabea1, Alireza Baradaran-Heravi2, Aruna D Balgi2
1Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, British Columbia V6T 1Z3, Canada.
Abstract:
Nonsense mutations introduce a premature termination codon (PTC) and are the underlying cause of multiple rare genetic diseases and cancers. Although certain aminoglycosides bind to eukaryotic ribosomes enabling incorporation of an amino acid at the PTC and formation of full-length protein, they are inefficient and toxic at therapeutic doses. Library screening in assays that measure readthrough at a PTC in the TP53 gene in human HDQ-P1 cells identified six novel 2-aminothiazole-4-carboxamide derivatives that potentiate the PTC readthrough (PTCR) efficiency of G418 when used in combination. The two most potent compounds incorporated a 4-indazole motif on the 2-aminothiazole nitrogen and a hydrophobic aryl substituent on the carboxamide nitrogen. These compounds are valuable tools to further investigate the therapeutic potential of aminoglycoside-induced PTCR.
Insights
Researchers identified novel compounds that enhance the readthrough of premature termination codons (PTCs). These compounds, when combined with G418, show potential for treating genetic diseases and cancers caused by PTCs.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Nonsense mutations lead to premature termination codons (PTCs), causing rare genetic diseases and cancers.
- Aminoglycosides can promote readthrough of PTCs but are limited by inefficiency and toxicity.
Purpose of the Study:
- To discover novel compounds that enhance premature termination codon readthrough (PTCR) in combination with existing drugs.
- To identify chemical structures that potentiate the therapeutic effects of G418 for PTC-related disorders.
Main Methods:
- Screening of novel 2-aminothiazole-4-carboxamide derivatives in a TP53 gene assay.
- Assessing the potentiation of G418-induced PTCR in human HDQ-P1 cells.
- Identifying lead compounds with specific structural motifs.
Main Results:
- Six novel 2-aminothiazole-4-carboxamide derivatives were identified that potentiate G418-induced PTCR.
- The two most effective compounds feature a 4-indazole motif and a hydrophobic aryl substituent.
- These compounds significantly enhance readthrough efficiency at PTCs.
Conclusions:
- Novel compounds can enhance the efficacy of G418 for premature termination codon readthrough.
- The identified compounds are promising tools for further research into PTC-related disease therapies.
- Further investigation into aminoglycoside-induced PTCR holds therapeutic potential.
Related Concept Videos
Termination of Translation
Termination of Translation
Estimation of k and VD of Aminoglycosides
Criteria for Aromaticity and the Hückel 4n + 2 Rule
For the first time, Eric Hückel, a German chemical physicist, derived a set of structural features for a compound to be classified as aromatic. This is now known as Hückel’s rule or the 4n +...
[4+2] Cycloaddition of Conjugated Dienes: Diels–Alder Reaction
Self-Evaluation: Self-Enhancement and Self-Verification

